Morgan Stanley Brainstorm Cell Therapeutics Inc. Transaction History

Morgan Stanley

$1.23 Trillion
Q1 2024

A detailed history of Morgan Stanley transactions in Brainstorm Cell Therapeutics Inc. stock. As of the latest transaction made, Morgan Stanley holds 40,098 shares of BCLI stock, worth $13,633. This represents 0.0% of its overall portfolio holdings.

Number of Shares

40,098

Previous 51,451 22.07%

Holding current value

$13,633

Previous $13,000 69.23%

% of portfolio

0.0%

Previous 0.0%

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	SELL	$0.28 - $0.66 $3,178 - $7,492	-11,353 Reduced 22.07%	40,098 $22,000
Q4 2023 Feb 13, 2024	BUY	$0.15 - $0.4 $3,134 - $8,358	20,896 Added 68.39%	51,451 $13,000
Q3 2023 Nov 15, 2023	BUY	$0.2 - $2.08 $323 - $3,363	1,617 Added 5.59%	30,555 $6,000
Q2 2023 Aug 14, 2023	SELL	$2.0 - $3.2 $19,784 - $31,654	-9,892 Reduced 25.48%	28,938 $59,000
Q1 2023 May 15, 2023	BUY	$1.43 - $3.3 $21,069 - $48,622	14,734 Added 61.15%	38,830 $128,000

Q4 2022 Feb 14, 2023	SELL	$1.37 - $3.39 $17,016 - $42,107	-12,421 Reduced 34.01%	24,096 $39,000
Q3 2022 Nov 14, 2022	SELL	$2.55 - $4.3 $11,385 - $19,199	-4,465 Reduced 10.9%	36,517 $162,000
Q2 2022 Oct 27, 2022	SELL	$2.71 - $3.6 $22,016 - $29,246	-8,124 Reduced 16.54%	40,982 $113,000
Q2 2022 Aug 15, 2022	SELL	$2.71 - $3.6 $22,016 - $29,246	-8,124 Reduced 16.54%	40,982 $113,000
Q1 2022 Oct 27, 2022	BUY	$2.92 - $4.19 $23,722 - $34,039	8,124 Added 19.82%	49,106 $164,000
Q1 2022 May 13, 2022	SELL	$2.92 - $4.19 $7,457 - $10,701	-2,554 Reduced 4.94%	49,106 $164,000
Q4 2021 Feb 14, 2022	SELL	$2.81 - $4.23 $2,399 - $3,612	-854 Reduced 1.63%	51,660 $207,000
Q3 2021 Nov 15, 2021	BUY	$3.14 - $4.09 $164,893 - $214,782	52,514 New	52,514 $174,000

Others Institutions Holding BCLI

# of Institutions

Shares Held

4.09M

Call Options Held

63.2K

Put Options Held

800

View Full List

About BRAINSTORM CELL THERAPEUTICS INC.

Ticker BCLI
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 36,486,200
Market Cap $12.4M
Description
Brainstorm Cell Therapeutics Inc., a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. The company, through its NurOwn proprietary cell therapy platform, leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem ...

More about BCLI

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

News

Stay updated on Morgan Stanley with notifications on news.

Account